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Beta-amyloid (Aβ) deposition in brain accumulates as a function of age in people with Down
syndrome (DS) with subsequent development into Alzheimer disease neuropathology, typically by
40 years of age. In vivo imaging using the Pittsburgh Compound B (PiB) ligand has facilitated
studies linking Aβ, cognition, and dementia in DS. However, there are no studies of PiB binding
across the lifespan in DS. The current study describes in vitro 3H-PiB binding in the frontal cortex
of autopsy cases with DS compared to non-DS controls. Tissue from 64 cases included controls
(N=25) and DS (N=39). In DS, 3H-PiB binding was significantly associated with age. After age 40
years in DS, 3H-PiB binding rose dramatically along with increasing individual variability. 3H-PiB
binding correlated with the amount of Aβ42. Using fixed frontal tissue and fluorescent 6-CN-PiB,
neuritic and cored plaques along with extensive cerebral amyloid angiopathy (CAA) showed 6CN-PiB binding. These results suggest that cortical PiB binding as shown by positron emission
tomography imaging reflects plaques and CAA in DS brain.
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1. Introduction
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Alzheimer disease (AD) is the most common cause of dementia in the elderly and affects 1
in 9 people over the age of 65 years (http://www.alz.org/facts/). There are currently no
biomarkers for AD that can clearly distinguish people who will develop the disease from
those who will not. The presence of beta-amyloid (Aβ) plaques and tau neurofibrillary
tangles determined at autopsy are defining characteristics for a pathological diagnosis of
AD. However, the development of in vivo ligands that selectively bind to Aβ, allows these
lesions to be visualized and quantified in people using positron emission tomography (PET),
significantly accelerating biomarker development (Cohen and Klunk, 2014;Johnson, et al.,
2012;Mintun, et al., 2006;Sperling, et al., 2014). The first of these ligands, Pittsburgh
Compound B (PiB) (Klunk, et al., 2004) has now been used in a large number of clinical
studies in patients with AD and can detect Aβ plaques in early disease (Cohen and Klunk,
2014).
3H-PiB

and 6-CN-PiB binding in vitro has been described in autopsy cases of AD in the
general population (Bacskai, et al., 2007;Beckett, et al., 2012;Ikonomovic, et al.,
2012;Ikonomovic, et al., 2008;Klunk, et al., 2007). Aβ40 and Aβ42 positive plaques as well
as vascular Aβ bind PiB in vitro. PiB binding was more robust in compact or cored plaques
and less so with diffuse plaques. Typically neurofibrillary tangles did not bind PiB except for
possible weak binding to extracellular “ghost” tangles, which may be due to associated Aβ
(Ikonomovic, et al., 2008). Finally, PiB binding correlates early in disease with postmortem
insoluble Aβ measures and with plaque loads. In one case that was PET imaged in life with
PiB and then came to autopsy, there was a significant overlap in the regional distribution of
the in vivo plaque binding and in vitro PiB binding (Bacskai, et al., 2007).

Author Manuscript

Down syndrome (DS) or trisomy 21, is the most common genetic cause of intellectual
disability and is associated with a neurologic phenotype that includes the development of
AD neuropathology by the age of 40 years (Head, et al., 2016;Lott, 2012;Lott and Dierssen,
2010). Further, autopsy studies indicate that in DS there is an age-associated progression of
AD neuropathology with initial deposits of Aβ and subsequent formation of neurofibrillary
tangles (Head, et al., 2016;Hof, et al., 1995;Leverenz, 1998;Wisniewski, et al., 1985). Even
so, the age of onset of dementia may be delayed by almost a decade (over 50 years of age)
after AD neuropathology is present and a subset of people with DS appear to not develop
dementia even at very old ages (Lai, 1989;Schupf, 2002).

Author Manuscript

PiB PET imaging studies in people with DS show that binding is age-dependent (Annus, et
al., 2016;Handen, et al., 2012;Hartley, et al., 2014;Landt, et al., 2011;Lao, et al., 2016). Two
of these studies included measures of impaired cognition and dementia status and found a
positive significant correlation with PiB load (Annus, et al., 2016;Hartley, et al., 2014).
Striatal PiB is the earliest site of binding with age in DS, typically observed after 35 years of
age (Annus, et al., 2016;Handen, et al., 2012;Lao, et al., 2016) and is similar to reports of
patients with presenilin-1 mutations (Klunk, et al., 2007;Koivunen, et al., 2008;Villemagne,
et al., 2009). Subsequently, with increasing age, more brain regions become affected
including the neocortex (Annus, et al., 2016).

Neurobiol Aging. Author manuscript; available in PMC 2018 June 01.

LeVine et al.

Page 3

Author Manuscript

The age-dependency of PiB binding in DS in vivo may be a biomarker for AD
neuropathology that can be used as an outcome measure in clinical trials. We hypothesized
that 3H-PiB binding would increase as a function of age in DS in frontal cortex. Thus, we
measured 3H-PiB binding biochemically in frontal cortex homogenates from autopsy cases
with and without DS. We used the highly fluorescent PiB derivative, 6-CN-PiB, which has
similar binding properties as PiB (Ikonomovic, et al., 2008;Mathis, et al., 2003) in fixed
tissue to visualize plaques and, if present, cerebral amyloid angiopathy (CAA) to determine
what types of pathology PiB binding represents in vivo.

2. Materials and methods
2.1 Autopsy cases

Author Manuscript

Frozen frontal cortex (Brodmann area 46) was obtained from 64 cases in total from the
University of Kentucky Alzheimer Disease Center, the Alzheimer Disease Research Center
at the University of California at Irvine, and the NIH NeuroBioBank. Human tissue
collection and handling conformed to each University’s Institutional Review Board
guidelines.
Cases ranged from 1 to 66 years of age (Table 1). Control cases were selected to match for
age and postmortem interval (PMI) to match the DS cases. Both males and females were
included in the study, but given the challenges of matching cases, we did not match for
gender. The level of premorbid intellectual disability or cognitive status was not available in
most cases and thus it was not possible to use these variables in the analysis.

Author Manuscript

The PMI was different across groups, with the control cases showing an overall longer PMI
(t(62)=3.0 p=.004) relative to DS cases. Correlation co-efficients were thus adjusted for PMI
when necessary.
2.2 3H-PiB binding
3H-PiB

Author Manuscript

binding was used to measure fibrillar Aβ and was assessed in homogenates of
frontal cortex (Beckett, et al., 2012;Matveev, et al., 2014). Instead of the 10 μM
concentrations typically used for histological assay, which will also bind to low affinity sites,
we used 1.2 nM PiB, a concentration closer to the Kd of the PiB analog CN-PiB for Aβ
pathology and to the in vivo concentration of 11C-PiB used to visualize high affinity PiB
binding in human AD brain. For binding studies, 20 μL of a PBS homogenate containing
0.166 mg wet weight tissue were added to each of three wells of a 96-well polypropylene
plate (Costar 3365). 200 μL of 1.2 nM 3H-PiB (cat. VT 278 specific radioactivity = 70.2 Ci/
mmol, Vitrax [Placentia, CA]) in PBS + 5% v/v EtOH was added to two of the wells (total
binding) and to the third well 200 μL of 1.2 nM 3H-PiB + 1 μM unlabeled competitor BTA-1
(non-specific binding) was added. The plate was sealed with plastic film. Samples were
incubated for 2 hours at room temperature without shaking, transferred to a 96-well
Millipore Multiscreen HTS Hi Flow FB (GF/B) filter plate, and filtered on a multi-well plate
vacuum manifold (Millipore Corporation, Bedford, MA). The filters were washed three
times with 200 μL of PBS + 5% v/v EtOH, dried, removed from the plate, and placed in
scintillation vials with 2 mL of BudgetSolve scintillation fluid and counted for 3H. Specific
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binding for each sample was calculated as total binding (mean CPM of the two filters from
wells containing radioactive PiB) minus non-specific binding (CPM value from the well
containing radioactive PiB + 1 μM nonradioactive BTA-1 competitor).
2.3 3H-X-34 binding
3H-X-34

binding (Matveev, et al., 2014) was used to measure a combination of fibrillar Aβ
and neurofibrillary tangles and was performed with 10 μl of a PBS homogenate containing
0.166 mg wet weight tissue similar to 3H-PiB binding, with 5 nM 3H-X-34, 23 Ci/mmol,
custom titrated by Vitrax) (Matveev, et al., 2014) with 10 μM Congo Red as the
nonradioactive X-34 competitor.
2.4 Aβ ELISA

Author Manuscript
Author Manuscript

To measure total soluble and insoluble Aβ40 and Aβ42 in frontal cortex, we used an ELISA.
The methods for tissue extraction and Aβ measurements have been published previously
(Beckett, et al., 2010). Briefly, frozen cortical samples were serially extracted to obtain
fractions of different assembly states of Aβ. The tissue was homogenized in a Dounce
homogenizer in ice cold phosphate buffered saline (PBS, pH 7.4) containing 1× complete
protease inhibitor cocktail (PIC) (Amresco, Solon, OH), and centrifuged at 20,800 × g for 30
minutes at 4°C. Following centrifugation, the supernatant was collected for subsequent
measures of PBS soluble Aβ and the pellets were sonicated (10 × 0.5 sec pulses at 100W,
Fisher Sonic Dismembrator) in room temperature 2% SDS in PBS with PIC followed by
centrifugation (as above, but at 14°C). The supernatant was again collected to measure SDS
soluble Aβ, and the remaining pellets were sonicated in 70% formic acid (FA) followed by
centrifugation at 20,800 × g for 1 hour at 4°C. The supernatant collected was used to
measure insoluble Aβ. Aβ was measured in these extracts using a standard, wellcharacterized two-site sandwich ELISA as described previously [47]. Briefly, an Immulon
4HBX plate (Dynex-Thermo Fisher) was coated with 0.5 μg/well of antibody, incubated
overnight at 4° C, then blocked with a solution of Synblock (AbD Serotec, Raleigh, NC), as
per the manufacturer’s instructions. Antigen capture was performed using monoclonal
antibody Ab9 (against Human Aβ(1–16)). Antigen detection was performed using
biotinylated antibodies 13.1.1. (end specific for Aβ(x-40)), and 12F4 (end specific for
Aβ(x-42); Covance, Princeton, NJ).

Author Manuscript

To measure insoluble Aβ, formic acid-soluble supernatant was initially neutralized by a 1:20
dilution in TP buffer (1 M Tris base, 0.5 M Na2HPO4), followed by a further dilution as
needed (1:100 to 1:400) in Antigen Capture buffer (AC) (0.02 M sodium phosphate buffer,
0.4 M NaCl, 2mM EDTA, 0.4% Block Ace (AbD Serotec), 0.05% NaN3, 0.2% BSA, 0.05%
CHAPS, pH 7). SDS-soluble fractions were diluted (1:20) in AC buffer alone and PBS
fractions were diluted 1:4 in AC buffer alone. A peptide standard curve of Aβ was run on the
same plate for comparison, and standards and samples were run at least in duplicate; Aβ
values were determined by interpolation relative to the standard curve. Plates were washed
2–4 times between assay steps with standard PBS containing 0.05% Tween-20 (2–4×)
followed by PBS (2–4×). Plates were developed with TMB reagent (Kirkegaard & Perry
Laboratories, Gaithersburg, MD), stopped with 6% o-phosphoric acid, and read at 450 nm
using a BioTek multiwell plate reader.
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To visually characterize plaque and vascular binding of PiB in vitro, we used fixed tissue
sections from the frontal cortex of two control cases (19 years and 51.3 years), DS (19.8
years), and DS with AD (DSAD) case (51.4 years) and the fluorescent cyano-PiB (CN-PiB).
Sections were first mounted on slides and allowed to dry prior to incubation in 100 nM CNPiB for 1 hour at RT using a similar protocol as published previously (Ikonomovic, et al.,
2008) but at a lower concentration closer to the CN-PiB Kd to focus on high affinity imaging
ligand-relevant binding. Slides were washed in PBS for 3× for 2 minutes then incubated
briefly (30s) in TrueBlack™ lipofuscin autofluorescence quencher (Biotium, Hayward, CA).
After three more 2-minute washes in PBS, slides were coverslipped using Everbrite™
mounting media (Biotium). Images were captured using an Olympus BX51 microscope with
a Q Color 5 digital camera. A second set of sections was first incubated in CN-PiB as
described above but prior to Trueblack quenching for autofluorescence, slides were
incubated in 0.5% thioflavine-S (Sigma-Aldrich, St. Louis, MO) in 50% ethanol,
differentiated in 50% ethanol, washed, and then exposed to TrueBlack. Sections were
coverslipped using Everbrite™.
2.6 Statistical analysis
SPSS for Windows and independent t-tests were used to test for PMI differences across the 2
groups (Control, DS). A stepwise linear regression was used to determine which outcome
measure best predicted age in DS cases. Spearman rank correlations were used to measure
the strength of association between specific 3H-PiB binding, 3H-X-34 binding, and age in
DS.

Author Manuscript

3. Results
3.13H-PiB binding
We tested the hypothesis that specific 3H-PiB binding levels would vary as a function of age
in DS. Fig. 1A shows a significant association between age at death in DS autopsy cases and
the amount of 3H-PiB binding that was not linear but rather increased dramatically in cases
over 40 years of age. A significant Spearman rank correlation between specific 3H-PiB
binding and age in DS was observed (r=0.54 p<0.0005 n=39), which remained after
controlling for PMI (r=0.35 p<0.03) but not in controls (selected to be pathology free).
Additional individual variability may be due to the presence or severity of dementia,
however these data were not available for this study.
3.2 3H-X-34 binding

Author Manuscript

We next tested the hypothesis that the highly-fluorescent Congo Red derivative, 3H-X-34,
which binds to a site on amyloid fibrils in plaques and neurofibrillary tangles and that is
distinct from the 3H-PiB binding site, would also vary with age in cases with DS. As
with 3H-PiB binding, we observed a significant increase in specific 3H-X-34 binding and
age of death (r=0.58 p<.0005 n=39) in DS (but not controls, selected to be pathology free)
(Fig.1B). However, this correlation was reduced with the inclusion of PMI when calculating
a partial correlation co-efficient (r=0.29 p=0.08).
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Predicting 3H-PiB and 3H-X-34 binding—Two independent stepwise linear regressions
were used to determine the best predictor of specific 3H-PiB or 3H-X-34 binding with PBS
soluble oligomers, PBS, SDS, and FA Aβ40 and Aβ42 levels included in the analysis. The
SDS Aβ42 fraction, the amount of oligomers, and the FA fraction of Aβ42 predicted
specific 3H-PiB binding (Table 2). In contrast, 3H-X-34 binding was best predicted by PBS
oligomers and the two FA fractions (Aβx-40 and Aβx-42) (Table 2). 3H-X-34 also binds to
neurofibrillary tangles, which were not systematically measured in the current study.
Interestingly, of all the measures that predict age in the DS autopsy series, specific 3H-PiB
binding was the best, not oligomers or Aβ measures (r=0.50, F(1,38)=12.47 p=0.001).
3.5 6-CN-PiB labeling in frontal cortex of DS and control cases

Author Manuscript

6-CN-PiB binding was not present at detectable levels in control cases (Fig. 2A and B) and
in a young case with DS (Fig.2C). The DSAD case showed significant amounts of 6-CN-PiB
labeling of plaques (Fig. 2D). In addition, substantial 6-CN-PiB binding to the vasculature
was observed in DSAD, consistent with CAA. Double label studies with thioflavine S
clearly show that 6-CN-PiB does not bind to neurofibrillary tangles in DSAD brain (Fig.
3A). Thioflavine S binds to the same site as Congo Red and 3H-X-34 and does not disturb 6CN-PiB binding. At higher magnification, 6-CN-PiB appears to bind to neuritic plaques
(Fig.3B). Further, 6-CN-PiB binds to the cores of plaques as thick fibrils with a halo of
thioflavine S-positive amyloid fibers on the periphery (Fig. 3C).

4. Discussion

Author Manuscript

The current study describes age-associated high affinity specific 3H-PiB and 3H-X-34
binding in autopsy cases with DS, which expands existing PiB PET studies in vivo in people
with DS to now include a broad range of ages from 1 to 66 years. Instead of the 10 μM
concentrations of ligand used for histology, which will also bind to low affinity sites, we use
100 nM CN-PiB, a concentration closer to the Kd of CN-PiB for Aβ pathology and to the in
vivo concentration of 11C-PiB used to visualize high affinity CN-PiB binding in human AD
brain. In DS, 3H-PiB binding increases rapidly after 40 years of age with variability between
individuals also increasing with age. 3H-PiB binding in DS appears to be best correlated
with Aβ42 levels (SDS and FA soluble) rather than Aβ40 peptide levels based on regression
analyses. 6-CN-PiB binding in autopsy cases shows a preference for fibrillar, cored, and
neuritic plaques along with CAA with no binding at these low concentrations to intracellular
neurofibrillary tangles (Ikonomovic, et al., 2008).

Author Manuscript

In the first report of autopsy correlates of 11C-PiB binding in vivo in sporadic AD, Bacskai
and colleagues showed overlap in immunostaining for Aβ and 11C-PiB binding in vitro,
including CAA (Bacskai, et al., 2007). Several studies now report 11C-PiB binding in
autopsy cases showing that in vitro binding to tissue sections, PiB binds to neuritic plaques
and weakly to diffuse plaques. Strong binding is observed in CAA and in some cases
labeling of extracellular tangles (Ikonomovic, et al., 2012;Ikonomovic, et al., 2008;Klunk, et
al., 2007). In a study of a PET 11C-PiB negative patient with mild cognitive impairment at
the time of the PET scan, but elevated CSF tau and reduced CSF Aβ, numerous diffuse Aβ
plaques and CAA were observed at autopsy suggesting either that there was insufficient

Neurobiol Aging. Author manuscript; available in PMC 2018 June 01.

LeVine et al.

Page 7

Author Manuscript
Author Manuscript

fibrillar Aβ to bind PiB in vivo (Cairns, et al., 2009) or that not all fibrillar forms of Aβ bind
to 11C-PiB. In a series of 6 older autopsy cases with PET 11C-PiB imaging, there was a
positive correlation between Aβ plaque counts and extent of PiB binding (Driscoll, et al.,
2012). Results from the current study also suggest that 3H-PiB binding in vitro in DS frontal
cortex is associated with neuritic plaques and CAA with weak or no labeling of diffuse
plaques in DS in the small set of cases we could examine. Thus, consistent with studies in
sporadic AD and in non-DS autopsy cases, it may also be the case that 6-CN-PiB binds only
a subset of Aβ deposits but not those within diffuse deposits in DS. Autopsy studies suggest
that diffuse plaques in DS appear prior to neuritic plaques (prior to 40 years of age) (Head,
et al., 2016) but PET PiB studies show a later age of onset of binding than that observed at
autopsy. In combination, these results may indicate that weak PiB binding precludes diffuse
plaque visualization by PET imaging. However, higher concentrations of CN-PiB in vitro
may allow it to bind to diffuse plaques in autopsy tissue and assessing more cases between
20–40 years of age will be helpful in future to establish this possible outcome.

Author Manuscript

In the current study, we show a broad range in 3H-PiB binding in the frontal DS cortex that
is strongly age-associated. In addition, by the inclusion of multiple measures of soluble and
insoluble Aβ40 and Aβ42 as well as oligomers, regression analyses show that SDS soluble
Aβ42 was the strongest predictor of PiB binding in DS but including the amount of
oligomers and insoluble Aβ42 improved the prediction of PiB binding. Our study confirms
and extends previous biochemical measures of PiB binding in autopsy tissue that suggest
binding in vivo by PET imaging is associated with the presence of insoluble Aβ (Kadir, et
al., 2011). Studies in autopsy tissue from the frontal cortex and hippocampus show
significantly higher amounts of PiB binding in clinically characterized AD cases compared
with age-matched clinically normal controls, although there can be some overlap (Ni, et al.,
2013). Further, total Aβ40 and Aβ42 measured by ELISA also correlates with PiB binding
in vitro in a case series of 5 AD and 5 control brains (Ni, et al., 2013). In a large case series
that included controls, preclinical AD, and AD samples, PiB binding correlated with
oligomeric Aβ, SDS soluble Aβ, and FA soluble Aβ (Beckett, et al., 2012).

Author Manuscript

The age-dependency of our biochemical measures of PiB binding in frontal cortex in DS
cases suggests a dramatic increase in PiB binding after the age of 40 years, which parallels
age-associated increases in insoluble Aβ42 (Cenini, et al., 2012). Previous studies of PiB
imaging in people with DS have included volunteers from 25 years and older and we now
provide data from autopsy samples as young as one year of age. Our in vitro binding assay
data are consistent with PET 11C-PiB imaging studies in people with DS typically showing
positive binding in cortex in participants over the age of 35 years (Annus, et al.,
2016;Handen, et al., 2012;Hartley, et al., 2014;Landt, et al., 2011;Lao, et al., 2016).
However, a caveat with our study is that we have a gap in DS autopsy cases when Aβ
typically begins to accumulate (25–40 years). This can be a challenge with DS autopsy
studies that are limited by the number of cases available. Further, we are not able to
determine if clinical status may be a better predictor of 3H-PiB binding in vitro given that
these data were not available on the current cases. Further, there as of yet is no consensus on
how best to characterize severity of dementia in people with DS as standardized tests such as
the MMSE, do not apply well in this cohort.
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Combined with the results of the current study, PiB binding in DS frontal cortex appears to
reflect primarily fibrillar Aβ42 as well as possibly extensive CAA, which may be
exacerbated in DS (Wilcock, et al., 2016). However, it should be stressed that in vitro, 3HPiB binding shows equivalent binding to both Aβ40 and Aβ42 (Klunk, et al., 2005). It may
also be the case that 3H-PiB binding reflects that there is more Aβ42 than Aβ40 in brain.
The significant individual variability we observe in DS autopsy studies particularly over 40
years of age may be due to the presence of dementia or to AD disease severity as suggested
in a study of sporadic AD (Beckett, et al., 2012) or in disease duration.
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We have focused on only the frontal cortex in the current study, which is a limitation given
that the earliest signs of PET 11C-PiB binding in DS are in the striatum (Annus, et al.,
2016;Handen, et al., 2012;Lao, et al., 2016). In these PET 11C-PiB binding studies, striatal
binding occurs between 36–40 years of age. A similar study using striatal samples would be
very interesting in this cohort of at-risk individuals and may reveal an earlier age of onset of
PiB binding in vitro; it would require more cases between 20–40 years. Unfortunately, we do
not as yet have frozen samples to make a similar comparison in this brain region. Future
studies will evaluate both the binding of 3H-PiB in frozen samples and CN-PiB in fixed
striatal samples with similar hypotheses. We may predict that striatal 3H-PiB would have an
earlier age of onset of increase in concentration than frontal cortex. It would also be critical
to determine if PiB is binding only to plaques and CAA in the striatum or if other
pathological features may be leading to enhanced binding. Ideally, cognitively characterized
autopsy cases would be included in future studies and may help account for individual
variability but these cases are a challenge to acquire currently.
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Fig. 1.

Age-Specific 3H-PiB and 3H-X-34 frontal cortex binding in DS. In DS, the extent of 3H-PiB
binding in the frontal cortex increased with age, with an exponential increase over the age of
40 years (A). 3H-X-34 binding was also significantly increased with age (B). This is in
contrast to 3H-PiB (C) and 3H-X-34 (D) binding in similarly aged control cases showing no
change as a function of age.
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Fig. 2.

6-CN-PiB binding in the frontal cortex of DS and control cases. 6-CN-PiB binding was not
observed in A. a 19-year old control case, B. a 19.8-year old DS case and, C. a 51-year old
middle aged control case. In contrast, D. shows abundant 6-CN-PiB binding in plaques
(arrowheads) and in CAA (arrows) in a 51.4 year old person with DS. Bar = 300 μm.
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Fig. 3.
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Double fluorescence labeling for 6-CN-PiB and thioflavine S in DS. (A) In a 51.4 year old
DS autopsy case, 6-CN-PiB (blue) bound to plaques (arrows) and CAA (arrowheads) and
could be distinguished from thioflavine S labeling of neurofibrillary tangles (green). (B) A
higher magnification of a single 6-CN-PiB positive plaque (arrow) shows the presence of
thioflavine S positive dystrophic neurites (arrowheads) in the periphery suggesting a neuritic
plaque. (C) In another 6-CN-PiB positive plaque (arrow), fibrils can be seen forming a
positive core of the plaque, whereas thioflavine S-positive fibrils were associated with the
periphery (arrow) and were also present in neurofibrillary tangles (arrowheads).
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Case demographics
Characteristic

DS

Control

N

39

25

Mean Age (range) years

44.1 (1–66)

36.4 (1–66)

PMI (hours)

9.6

15.2

Female (%)

20 (59)

10 (40)
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Stepwise regression analysis of best predictors for PiB and 3H-X-34binding
Dependent

Specific PiB

Specific 3H-X-34

Model

R

R Square

Adjusted R Square

SDS Aβ42

0.711

0.506

0.499

SDS Aβ42 + Oligomers

0.788

0.621

0.610

SDS Aβ42 + Oligomers + FA Aβ42

0.811

0.658

0.643

Oligomers

0.650

0.423

0.414

Oligomers + FA Aβ 40

0.734

0.539

0.525

Oligomers + FA Aβ 40+FA Aβ 42

0.760

0.577

0.558
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